TGTX
TG Therapeutics, Inc.
Phase 3
Confirmed
BRIUMVI (ublituximab-xiiy)
relapsing forms of multiple sclerosis (RMS)
41d ago
May 27, 2026
SEC 8-K
verified 14h ago
Countdown card →